Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NOTV Stock Forecast 2026-2027
$0.61
Current Price
$20.63M
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to NOTV Price Targets
+1,375.4%
To High Target of $9.00
+391.8%
To Median Target of $3.00
+309.8%
To Low Target of $2.50
NOTV Price Momentum
-3.2%
1 Week Change
-12.9%
1 Month Change
-85.7%
1 Year Change
+8.9%
Year-to-Date Change
-87.3%
From 52W High of $4.80
+29.8%
From 52W Low of $0.47
📊 TOP ANALYST CALLS
Did NOTV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Inotiv is one of their latest high-conviction picks.
Latest NOTV Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, NOTV has a bullish consensus with a median price target of $3.00 (ranging from $2.50 to $9.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.61, the median forecast implies a 391.8% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Timothy Daley at Wells Fargo, projecting a 1,375.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NOTV Analyst Ratings
2
Buy
1
Hold
0
Sell
NOTV Price Target Range
Low
$2.50
Average
$3.00
High
$9.00
Current: $0.61
Latest NOTV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NOTV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 4, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $3.00 |
| May 8, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $5.00 |
| Sep 30, 2024 | Lake Street | Frank Takkinen | Buy | Upgrade | $4.00 |
| May 16, 2024 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $10.00 |
| May 16, 2024 | Lake Street | Frank Takkinen | Hold | Downgrade | $2.00 |
| May 14, 2024 | Jefferies | David Windley | Hold | Downgrade | $3.75 |
| Feb 9, 2024 | Jefferies | David Windley | Buy | Upgrade | $11.50 |
| Dec 12, 2023 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $25.00 |
| Jul 20, 2023 | Wells Fargo | Timothy Daley | Overweight | Initiates | $9.00 |
| Jan 19, 2023 | Jefferies | David Windley | Hold | Downgrade | $8.00 |
| Jan 11, 2023 | Lake Street | Frank Takkinen | Buy | Upgrade | $10.00 |
| Nov 18, 2022 | Lake Street | Frank Takkinen | Hold | Downgrade | $7.00 |
| Oct 4, 2022 | Jefferies | David Windley | Buy | Initiates | $27.00 |
| Aug 11, 2022 | Lake Street | Frank Takkinen | Buy | Maintains | $60.00 |
| Jan 31, 2022 | Lake Street | Buy | Initiates | $N/A | |
| Sep 20, 2021 | Craig-Hallum | Buy | Initiates | $N/A |
Inotiv Inc. (NOTV) Competitors
The following stocks are similar to Inotiv based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Inotiv Inc. (NOTV) Financial Data
Inotiv Inc. has a market capitalization of $20.63M with a P/E ratio of -0.3x. The company generates $513.02M in trailing twelve-month revenue with a -13.4% profit margin.
Revenue growth is +5.9% quarter-over-quarter, while maintaining an operating margin of -10.3% and return on equity of -44.8%.
Valuation Metrics
Market Cap
$20.63M
Enterprise Value
$458.10M
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
+5.9%
Gross Margin
+23.9%
Operating Margin
-10.3%
Net Margin
-13.4%
EPS Growth
+5.9%
Financial Health
Cash/Price Ratio
+103.8%
Current Ratio
0.3x
Debt/Equity
337.6x
ROE
-44.8%
ROA
-3.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Inotiv Inc. (NOTV) Business Model
About Inotiv Inc.
What They Do
Provides contract research organization services.
Business Model
Inotiv Inc. operates as a contract research organization (CRO), offering a range of non-clinical and analytical services to pharmaceutical and biotechnology companies. The company generates revenue by assisting clients in drug discovery and development, particularly through toxicology and pathology studies, bioanalysis, and consulting. By ensuring safety and efficacy standards during the early stages of drug development, Inotiv helps clients expedite the process of bringing new therapies to market.
Additional Information
Headquartered in the United States, Inotiv serves a global clientele and is positioned in a rapidly evolving healthcare sector. Its expertise in navigating complex regulatory environments makes it a valuable partner for clients aiming to innovate in therapeutic solutions.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
1,977
CEO
Mr. Robert W. Leasure Jr.
Country
United States
IPO Year
1997
Website
www.inotiv.comInotiv Inc. (NOTV) Latest News & Analysis
Latest News
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities
1 month ago
Quick Summary
Inotiv, Inc. has partnered with VUGENE to enhance AI-assisted drug discovery and improve data insights in drug development, focusing on nonclinical and analytical research services.
Why It Matters
Inotiv's collaboration with VUGENE signals a strategic shift towards AI in drug discovery, potentially boosting efficiency and innovation, which could enhance competitive advantage and drive stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Inotiv, Inc. (NOTV) held its Q4 2025 earnings call, discussing financial performance and outlook. Further details may provide insights into the company’s growth and profitability.
Why It Matters
Inotiv's Q4 2025 earnings call provides insights into financial performance, strategic direction, and market positioning, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
1 month ago
Quick Summary
Fiscal Q4 2025 revenue rose 5.9% to $138.1M; total fiscal 2025 revenue increased 4.5% to $513M. Operating loss decreased significantly. Conference call at 4:30 PM ET today.
Why It Matters
Steady revenue growth and significant reduction in operating losses indicate improving financial health, potentially boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A contract research organization (CRO) reports a 448% revenue growth from FY 2021 to FY 2024, driven by strategic expansion and service development focused on client needs.
Why It Matters
A 448% revenue growth signals strong business performance and potential for future profitability, making the company an attractive investment opportunity.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Inotiv, Inc. (NASDAQ: NOTV) will release its fiscal 2025 Q4 and full-year financial results on December 3, 2025, after market close, followed by a conference call at 4:30 PM ET.
Why It Matters
Inotiv's upcoming financial results announcement could influence stock performance, providing insights into the company's growth and profitability, impacting investor sentiment and trading strategies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oversold stocks in the health care sector may offer investment opportunities in undervalued companies.
Why It Matters
Oversold health care stocks indicate potential undervaluation, suggesting a buying opportunity that could result in significant returns as market conditions normalize.
Source: Benzinga
Market Sentiment:
Positive
Frequently Asked Questions About NOTV Stock
What is Inotiv Inc.'s (NOTV) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Inotiv Inc. (NOTV) has a median price target of $3.00. The highest price target is $9.00 and the lowest is $2.50.
Is NOTV stock a good investment in 2026?
According to current analyst ratings, NOTV has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NOTV stock?
Wall Street analysts predict NOTV stock could reach $3.00 in the next 12 months. This represents a 391.8% increase from the current price of $0.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Inotiv Inc.'s business model?
Inotiv Inc. operates as a contract research organization (CRO), offering a range of non-clinical and analytical services to pharmaceutical and biotechnology companies. The company generates revenue by assisting clients in drug discovery and development, particularly through toxicology and pathology studies, bioanalysis, and consulting. By ensuring safety and efficacy standards during the early stages of drug development, Inotiv helps clients expedite the process of bringing new therapies to market.
What is the highest forecasted price for NOTV Inotiv Inc.?
The highest price target for NOTV is $9.00 from Timothy Daley at Wells Fargo, which represents a 1,375.4% increase from the current price of $0.61.
What is the lowest forecasted price for NOTV Inotiv Inc.?
The lowest price target for NOTV is $2.50 from at , which represents a 309.8% increase from the current price of $0.61.
What is the overall NOTV consensus from analysts for Inotiv Inc.?
The overall analyst consensus for NOTV is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are NOTV stock price projections?
Stock price projections, including those for Inotiv Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 3:45 AM UTC